Accepted Article
Received Date : 23-Feb-2014 Revised Date : 26-Jun-2014 Accepted Date : 12-Aug-2014 Article type
: Original Article
Colchicine Levels in Chronic Kidney Diseases and Kidney Transplant Recipients using Tacrolimus
Anara Amanova, MD, Ankara University School of Medicine, Department of Internal Medicine Zeynep Kendi Celebi, MD, Ankara University School of Medicine, Department of Nephrology Filiz Bakar, PhD, Ankara University School of Pharmacy, Department of Biochemistry Mehmet Gokhan Caglayan, PhD, Ankara University School of Pharmacy, Department of Analytical Chemistry Kenan Keven, MD, Professor, Ankara University, Faculty of Medicine, Department of Nephrology
Running Head: Colchicine Levels in Kidney Diseases
Corresponding Author: Zeynep Kendi Celebi
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ctr.12448 This article is protected by copyright. All rights reserved.
Accepted Article
Ankara University School of Medicine Nephrology Department, Ibni Sina Hospital 14th Floor Postal code:06100 Samanpazari Altindag/ANKARA TURKEY Telephone : +90532548618/+903125082603 Fax: +903125083166 Email Adress: [email protected]
Amanova A, Celebi ZK, Bakar F, Caglayan MG, Keven K
Colchicine Levels in Chronic Kidney Diseases and Kidney Transplant Recipients using Tacrolimus
Title of Journal: Clinical Transplantation
Abstract Background: Tacrolimus is a CYP3A4 inhibitor and can alter colchicine metabolism. In this study, we aimed to evaluate plasma colchicine levels in different stages of kidney disease as well as in kidney transplant (KTx) recipients using tacrolimus.
Method: This study included 6 FMF patients with normal glomerular filtration rate (GFR) as controls, 3 patients with low GFR, 6 FMF patients on hemodialysis (HD), and 6 FMF patients who were KTx recipients using tacrolimus. After a three-day washout period, plasma colchicine levels were measured at 0 (pre-dose), 1,2,4,8, and 24 hours
This article is protected by copyright. All rights reserved.
Accepted Article
post-dose of 1 mg oral colchicine. Area under the curve 0-24 hours (AUC0-24) and maximum concentration (Cmax) were evaluated and compared between the groups.
Results: Colchicine AUC0-24 was 6-fold higher in HD (p
Received Date : 23-Feb-2014 Revised Date : 26-Jun-2014 Accepted Date : 12-Aug-2014 Article type
: Original Article
Colchicine Levels in Chronic Kidney Diseases and Kidney Transplant Recipients using Tacrolimus
Anara Amanova, MD, Ankara University School of Medicine, Department of Internal Medicine Zeynep Kendi Celebi, MD, Ankara University School of Medicine, Department of Nephrology Filiz Bakar, PhD, Ankara University School of Pharmacy, Department of Biochemistry Mehmet Gokhan Caglayan, PhD, Ankara University School of Pharmacy, Department of Analytical Chemistry Kenan Keven, MD, Professor, Ankara University, Faculty of Medicine, Department of Nephrology
Running Head: Colchicine Levels in Kidney Diseases
Corresponding Author: Zeynep Kendi Celebi
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ctr.12448 This article is protected by copyright. All rights reserved.
Accepted Article
Ankara University School of Medicine Nephrology Department, Ibni Sina Hospital 14th Floor Postal code:06100 Samanpazari Altindag/ANKARA TURKEY Telephone : +90532548618/+903125082603 Fax: +903125083166 Email Adress: [email protected]
Amanova A, Celebi ZK, Bakar F, Caglayan MG, Keven K
Colchicine Levels in Chronic Kidney Diseases and Kidney Transplant Recipients using Tacrolimus
Title of Journal: Clinical Transplantation
Abstract Background: Tacrolimus is a CYP3A4 inhibitor and can alter colchicine metabolism. In this study, we aimed to evaluate plasma colchicine levels in different stages of kidney disease as well as in kidney transplant (KTx) recipients using tacrolimus.
Method: This study included 6 FMF patients with normal glomerular filtration rate (GFR) as controls, 3 patients with low GFR, 6 FMF patients on hemodialysis (HD), and 6 FMF patients who were KTx recipients using tacrolimus. After a three-day washout period, plasma colchicine levels were measured at 0 (pre-dose), 1,2,4,8, and 24 hours
This article is protected by copyright. All rights reserved.
Accepted Article
post-dose of 1 mg oral colchicine. Area under the curve 0-24 hours (AUC0-24) and maximum concentration (Cmax) were evaluated and compared between the groups.
Results: Colchicine AUC0-24 was 6-fold higher in HD (p
